This comprehensive report provides a detailed analysis of the global long-acting antipsychotic market, projecting growth and trends from 2025 through 2032. The study examines key market drivers and opportunities across various product types, such as Aripiprazole and Risperidone, and applications including schizophrenia and bipolar disorder. By evaluating major players like Janssen and Teva, the report explores regional dynamics in the Americas, APAC, and Europe to offer strategic insights into market share, competitive positioning, and emerging industry developments.

Market Overview

The global Long-acting Antipsychotic market is projected to experience significant growth from 2025 through 2032, maintaining a steady compound annual growth rate throughout the forecast period.

Regional Market Projections

• United States: The market for Long-acting Antipsychotics in the United States is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• China: The market for Long-acting Antipsychotics in China is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.
• Europe: The market for Long-acting Antipsychotics in Europe is estimated to increase from 2025 through 2032, growing at a consistent compound annual growth rate.

Report Scope and Methodology

Produced by LP Information, Inc. (LPI), the “Long-acting Antipsychotic Industry Forecast” reviews total global Long-acting Antipsychotic sales in 2025 and provides a comprehensive analysis of projected sales for the period from 2026 through 2032. The report offers a detailed analysis in US$ millions, broken down by region, market sector, and sub-sector.

This Insight Report provides a comprehensive analysis of the global Long-acting Antipsychotic landscape, highlighting key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyzes the strategies of leading global companies, focusing on their Long-acting Antipsychotic portfolios and capabilities, market entry strategies, market positions, and geographic footprints to understand their unique positions in an accelerating global market. Using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, the study evaluates key market trends, drivers, and affecting factors to highlight emerging pockets of opportunity.

Market Segmentation

By Type

• Aripiprazole
• Haloperidol
• Paliperidone
• Risperidone
• Olanzapine
• Others

By Application

• Schizophrenia
• Bipolar Disorder
• Others

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Global key players in the Long-acting Antipsychotic market include Oakwood Labs, Teva, MedinCell, Janssen, and Otsuka America Pharmaceutical, Inc. In 2025, the two largest companies globally held a significant portion of the market share.

The following companies have been profiled based on primary expert input and analysis of their coverage, product portfolio, and market penetration:

• Oakwood Labs
• Teva
• MedinCell
• Janssen
• Otsuka America Pharmaceutical, Inc.
• Lundbeck
• Eli Lilly
• Alkermes
• Par Pharmaceutical
• AbbVie
• Luye Pharmaceutical

Key Questions Addressed

• What is the 10-year outlook for the global Long-acting Antipsychotic market?
• What factors are driving Long-acting Antipsychotic market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Long-acting Antipsychotic market opportunities vary by end market size?
• How does Long-acting Antipsychotic break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Long-acting Antipsychotic Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Long-acting Antipsychotic by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Long-acting Antipsychotic by Country/Region, 2021, 2025 & 2032

  • 2.2 Long-acting Antipsychotic Segment by Type

    • 2.2.1 Aripiprazole

    • 2.2.2 Haloperidol

    • 2.2.3 Paliperidone

    • 2.2.4 Risperidone

    • 2.2.5 Olanzapine

    • 2.2.6 Others

    • 2.2.7 Long-acting Antipsychotic Sales by Type

      • 2.2.7.1 Global Long-acting Antipsychotic Sales Market Share by Type (2021-2026)
      • 2.2.7.2 Global Long-acting Antipsychotic Revenue and Market Share by Type (2021-2026)
      • 2.2.7.3 Global Long-acting Antipsychotic Sale Price by Type (2021-2026)

  • 2.3 Long-acting Antipsychotic Segment by Application

    • 2.3.1 Schizophrenia

    • 2.3.2 Bipolar Disorder

    • 2.3.3 Others

    • 2.3.4 Long-acting Antipsychotic Sales by Application

      • 2.3.4.1 Global Long-acting Antipsychotic Sale Market Share by Application (2021-2026)
      • 2.3.4.2 Global Long-acting Antipsychotic Revenue and Market Share by Application (2021-2026)
      • 2.3.4.3 Global Long-acting Antipsychotic Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Long-acting Antipsychotic Breakdown Data by Company

    • 3.1.1 Global Long-acting Antipsychotic Annual Sales by Company (2021-2026)

    • 3.1.2 Global Long-acting Antipsychotic Sales Market Share by Company (2021-2026)

  • 3.2 Global Long-acting Antipsychotic Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Long-acting Antipsychotic Revenue by Company (2021-2026)

    • 3.2.2 Global Long-acting Antipsychotic Revenue Market Share by Company (2021-2026)

  • 3.3 Global Long-acting Antipsychotic Sale Price by Company

  • 3.4 Key Manufacturers Long-acting Antipsychotic Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Long-acting Antipsychotic Product Location Distribution

    • 3.4.2 Players Long-acting Antipsychotic Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Long-acting Antipsychotic by Geographic Region

  • 4.1 World Historic Long-acting Antipsychotic Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Long-acting Antipsychotic Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Long-acting Antipsychotic Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Long-acting Antipsychotic Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Long-acting Antipsychotic Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Long-acting Antipsychotic Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Long-acting Antipsychotic Sales Growth

  • 4.4 APAC Long-acting Antipsychotic Sales Growth

  • 4.5 Europe Long-acting Antipsychotic Sales Growth

  • 4.6 Middle East & Africa Long-acting Antipsychotic Sales Growth

• 5 Americas

  • 5.1 Americas Long-acting Antipsychotic Sales by Country

    • 5.1.1 Americas Long-acting Antipsychotic Sales by Country (2021-2026)

    • 5.1.2 Americas Long-acting Antipsychotic Revenue by Country (2021-2026)

  • 5.2 Americas Long-acting Antipsychotic Sales by Type (2021-2026)

  • 5.3 Americas Long-acting Antipsychotic Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Long-acting Antipsychotic Sales by Region

    • 6.1.1 APAC Long-acting Antipsychotic Sales by Region (2021-2026)

    • 6.1.2 APAC Long-acting Antipsychotic Revenue by Region (2021-2026)

  • 6.2 APAC Long-acting Antipsychotic Sales by Type (2021-2026)

  • 6.3 APAC Long-acting Antipsychotic Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Long-acting Antipsychotic by Country

    • 7.1.1 Europe Long-acting Antipsychotic Sales by Country (2021-2026)

    • 7.1.2 Europe Long-acting Antipsychotic Revenue by Country (2021-2026)

  • 7.2 Europe Long-acting Antipsychotic Sales by Type (2021-2026)

  • 7.3 Europe Long-acting Antipsychotic Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Long-acting Antipsychotic by Country

    • 8.1.1 Middle East & Africa Long-acting Antipsychotic Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Long-acting Antipsychotic Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Long-acting Antipsychotic Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Long-acting Antipsychotic Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Long-acting Antipsychotic

  • 10.3 Manufacturing Process Analysis of Long-acting Antipsychotic

  • 10.4 Industry Chain Structure of Long-acting Antipsychotic

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Long-acting Antipsychotic Distributors

  • 11.3 Long-acting Antipsychotic Customer

• 12 World Forecast Review for Long-acting Antipsychotic by Geographic Region

  • 12.1 Global Long-acting Antipsychotic Market Size Forecast by Region

    • 12.1.1 Global Long-acting Antipsychotic Forecast by Region (2027-2032)

    • 12.1.2 Global Long-acting Antipsychotic Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Long-acting Antipsychotic Forecast by Type (2027-2032)

  • 12.7 Global Long-acting Antipsychotic Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Oakwood Labs

    • 13.1.1 Oakwood Labs Company Information

    • 13.1.2 Oakwood Labs Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.1.3 Oakwood Labs Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Oakwood Labs Main Business Overview

    • 13.1.5 Oakwood Labs Latest Developments

  • 13.2 Teva

    • 13.2.1 Teva Company Information

    • 13.2.2 Teva Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.2.3 Teva Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Teva Main Business Overview

    • 13.2.5 Teva Latest Developments

  • 13.3 MedinCell

    • 13.3.1 MedinCell Company Information

    • 13.3.2 MedinCell Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.3.3 MedinCell Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 MedinCell Main Business Overview

    • 13.3.5 MedinCell Latest Developments

  • 13.4 Janssen

    • 13.4.1 Janssen Company Information

    • 13.4.2 Janssen Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.4.3 Janssen Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Janssen Main Business Overview

    • 13.4.5 Janssen Latest Developments

  • 13.5 Otsuka America Pharmaceutical, Inc.

    • 13.5.1 Otsuka America Pharmaceutical, Inc. Company Information

    • 13.5.2 Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.5.3 Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Otsuka America Pharmaceutical, Inc. Main Business Overview

    • 13.5.5 Otsuka America Pharmaceutical, Inc. Latest Developments

  • 13.6 Lundbeck

    • 13.6.1 Lundbeck Company Information

    • 13.6.2 Lundbeck Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.6.3 Lundbeck Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Lundbeck Main Business Overview

    • 13.6.5 Lundbeck Latest Developments

  • 13.7 Eli Lilly

    • 13.7.1 Eli Lilly Company Information

    • 13.7.2 Eli Lilly Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.7.3 Eli Lilly Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Eli Lilly Main Business Overview

    • 13.7.5 Eli Lilly Latest Developments

  • 13.8 Alkermes

    • 13.8.1 Alkermes Company Information

    • 13.8.2 Alkermes Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.8.3 Alkermes Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Alkermes Main Business Overview

    • 13.8.5 Alkermes Latest Developments

  • 13.9 Par Pharmaceutical

    • 13.9.1 Par Pharmaceutical Company Information

    • 13.9.2 Par Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.9.3 Par Pharmaceutical Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Par Pharmaceutical Main Business Overview

    • 13.9.5 Par Pharmaceutical Latest Developments

  • 13.10 AbbVie

    • 13.10.1 AbbVie Company Information

    • 13.10.2 AbbVie Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.10.3 AbbVie Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.10.4 AbbVie Main Business Overview

    • 13.10.5 AbbVie Latest Developments

  • 13.11 Luye Pharmaceutical

    • 13.11.1 Luye Pharmaceutical Company Information

    • 13.11.2 Luye Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications

    • 13.11.3 Luye Pharmaceutical Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.11.4 Luye Pharmaceutical Main Business Overview

    • 13.11.5 Luye Pharmaceutical Latest Developments

• 14 Research Findings and Conclusion